Lightcalls.com
 

A of recent origin US "risk-based"...

A of recent origin US "risk-based" consolidation model has been imported into Canadian practice. Accounting Guideline 15 "Consolidation of Variable Interest Entities" (AcG-15) is the accounting profession's answer to the financial services industry's ingenuity and creativity in creating evermore more complex financial structures. The modern standard extends consolidation requirements beyond entities expose to voting control, making it possible for common entity to consolidate another without holding any voting shares. AcG-15 greatly expands the circumstances below which consolidation is required.

Remember Enron's use of "special object entities" (which are included within the universal of "variable interest entities") to extract depreciable assets and indebtedness from its consolidated financial statements? Enron was able, subject to the rules existing at that time, to avoid consolidating these pure assets while remaining exposed, on contract, to some or all of the risks associated with them. nevertheless the non-consolidation of its special sense entities wasn't the singular cause of Enron's ultimate failure, there present the appearances to be a consensus that Enron's consolidated financial statements did not reflect-fairly, and in all material respects-its financial position, proceeds of operations, and/or cash flow

Practitioners who don't have experience with structur financial arrangements will likely find AcG-15 a surpassingly difficult standard to read and understand. This is partly proper to the fact that the language in the standard is vague and highly generalized; if it be not that while easy to criticize, this aspect of the standard is necessary to render certain the adequacy of the standard's scope



The following article is an attempt the give small and mid-size practitioners any practical guidance on the impact AcG-15 will have upon privately held businesses. It is by means of no means a comprehensive analysis of the standard.

Understanding the impact of AcG-15

The best way to understand AcG-15's implications is to turn the thoughts at its impact on a man and wife of simple fact patterns:

Example #1

Consider a case where a husband hies a successful business owned at a corporation he controls (let's call it Opco") imagine that the husband's corporation loans a large totality of money-say $100,000-without security to a corporation ("Lossco") wholly concedeed by a corporation controlled at his wife ("Spouseco"). Lossco is doing poorly and urgencys financing. Spouseco's interest in Lossco is limited to $100 of share capital and a $20000 loan, all of which has been thrown away in the normal course of business.

Using the traditional understanding of consolidation, Opco would not consolidate Lossco as it hem ins no Lossco shares; Spouseco, holding 100% of Lossco's shares, would consolidate Lossco However, beneath the new risk-based concept of consolidation, Opco must consolidate Lossco because Opco is the primary beneficiary of a variable interest entity. Understanding for what purpose this is so requires a careful review of the AcG-15 fundamentals.

Variable interest entities (VIEs)

What is an "interest"?

The bound "interest" in the context of this standard includes loans, shares, and just about any other contractual relationship with another entity; however, this is only a working definition given the virtually unlimited grade of complexity inherent in the standard.

For privately held enterprises, interests include the four in the greatest degree common relationships: common shares, redeemable preferr shares, loans, and loan guarantees.

What is a "variable" interest?

The universal of a variable interest is better understood when contrasted with that of a fixed interest. admitting not defined in AcG-15, a fixed interest has a value ("fair value," which means in what way much you could sell it for) that does not change, irrespective of the activities of the borrower or investee1; for example, a loan secur from land would normally be viewed as a fixed interest.

Common feeling would indicate that most interests are not fixed interests, as the value of in the greatest degree loans, shares, and other interests will vary through time.

Fixed interests are likely to be rare in the words immediately preceding [i]or[/i] following of privately held businesses- limited to interests supported from substantial security, such as loans secur from land or meaningful guarantees, where the guarantor is unlikely to default. still even in these cases, the circumstances would have to be carefully considered onward a case-by-case basis; for example, a loan secur according to land could be a variable interest if the value of the land is insufficient to repay the loan.

What is a "variable interest entity"?

Variable interests are commonly contested in the business world, whether on design or circumstance.

Variability alone does not trigger a requirement to consolidate. Consolidation becomes a possibility when individual of the following three criteria (which use a variable interest into an interest in a VIE), are met:

1) The entity has insufficient equity capital at risk to stock its operations without additional financing; or

2) The equity proprietors as a group do not posses single of three fundamental characteristics: a) curb b) the obligation to absorb awaited losses, or c) the right to receive anticipateed residual returns; or



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.